Clinical trials: Inflammatory Myopathy
Inflammation;Muscle(S), Oxidative Stress Injury
Effect of 8-week Supplementation With Black Chokeberry on Recovery in Highly Trained Rowers
Purpose: To analyze the effects of 8-week supplementation with anthocyanin compounds contained in black chokeberry (Aronia melanocarpa) on indicators of inflammation and oxidative stress.
- Conditions
- Inflammation;Muscle(S), Oxidative Stress Injury, Permeability; Increased
- Trial name
- NCT06133751
- Testing
- black chokeberry (Aronia melanocarpa)
- Where
- Poland
- Volunteers
- 15 people
- Sponsor
- Poznan University of Physical Education
Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM)
Safety Study of CC312 in Autoimmune Disease Patients
This study is an open-label, multiple-dose escalation, Investigator-Initiated Trial (IIT) clinical trial designed to evaluate the safety and tolerability of CC312 in adult patients with relapsed and refractory autoimmune…
- Conditions
- Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA)
- Trial name
- NCT06888960
- Testing
- CC312
- Where
- China
- Volunteers
- 18 people
- Sponsor
- CytoCares Inc
Dermatomyositis
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)
This is a phase 3, multicenter, randomized, placebo-controlled, double-blind study of IgPro20 (subcutaneous Ig) treatment in adult subjects with dermatomyositis (DM).
- Trial name
- RECLAIIM (NCT04044690)
- Testing
- human immunoglobulin G
- Where
- 76 sites in United States, Argentina and 12 more
- Volunteers
- 134 people
- Sponsor
- CSL Behring
Dermatomyositis, Polymyositis
Dermatomyositis and Polymyositis Registry
By creating a registry, physicians will have the opportunity to understand the clinical outcomes of Myositis patients treated with Acthar.
- Trial name
- ADAPT (NCT01637064)
- Testing
- Acthar
- Where
- 5 sites in United States
- Volunteers
- 100 people
- Sponsor
- Phoenix Neurological Associates, LTD
Dermatomyositis
Study of IFN-K in Dermatomyositis
This study is a Proof of Concept study aiming to evaluate the production of anti-IFNα antibodies (immune response) in adult subjects with dermatomyositis
- Trial name
- NCT02980198
- Testing
- IFN-Kinoid, ISA 51
- Where
- 8 sites in France, Germany and 2 more
- Sponsor
- Neovacs
Behcet's Disease, Idiopathic Inflammatory Myopathies
Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases
Research into novel therapies for rare, immune-mediated inflammatory diseases (IMIDs) is limited due to small patient populations.
- Conditions
- Behcet's Disease, Idiopathic Inflammatory Myopathies, IgG4-related Disease
- Trial name
- DRIMID (NCT06285539)
- Testing
- Filgotinib
- Where
- 6 sites in Netherlands
- Volunteers
- 60 people
- Sponsor
- UMC Utrecht
Lupus, Dermatomyositis, Juvenile
Teams Engaged in Accessible Mental Health Interventions for Lupus Erythematosus and Dermatomyositis Stress
The objectives of this study are to determine if the 'Teams Engaged in Accessible Mental Health Interventions for Lupus Erythematosus and Dermatomyositis Stress' (TEAM-LEADS) intervention is feasible and acceptable to adolescents…
- Conditions
- Lupus, Dermatomyositis, Juvenile, Dermatomyositis, Lupus Erythematosus
- Trial name
- TEAM-LEADS (NCT06999109)
- Testing
- TEAM-LEADS
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Duke University
Dermatomyositis
Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis
This is a Phase 2/3, double-blind, randomized, placebo-controlled, parallel group, multicenter study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of ravulizumab in adult participants…
- Trial name
- NCT04999020
- Testing
- Ravulizumab
- Where
- 111 sites in United States, Australia and 11 more
- Volunteers
- 38 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Giant Cell Arteritis (GCA), Polymyalgia Rheumatica (PMR)
AYLo - AutoimmunitY and Loss of y
The AYLo study (AutoimmunitY and Loss of y - Investigating the Role of Hematopoietic Mutations and Mosaic Mutation in the Y Chromosome in Autoimmune Rheumatologic Diseases) aims to systematically investigate hematopoietic…
- Conditions
- Giant Cell Arteritis (GCA), Polymyalgia Rheumatica (PMR), ANCA Associated Vasculitis (AAV), Idiopathic Inflammatory Myopathies
- Trial name
- AYLo (NCT06696027)
- Testing
- Single nucleotide polymorphisms (SNP), 3'mRNA sequencing, Enzyme-linked immunosorbent assay (ELISA) and Legendplex Array
- Where
- Germany
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- University of Bonn
Critical Illness Myopathy, Myopathy Critical Illness
Understanding the Mechanisms of Critical Illness Myopathy by Use of a Novel Electrophysiological Method - MVRCs
Critical illness myopathy (CIM) is a disabling condition that develops in critically ill patients. The syndrome is not only a cause of prolonged intensive care hospitalisation but also a main reason for delayed recovery.
- Trial name
- NCT04711070
- Where
- 2 sites in Denmark
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Sándor Beniczky
Chronic Disease
Integrative Therapy of Chronic Diseases
The observational study aims to investigate the extent to which a two-week stay in an internal medicine clinic for integrative medicine and naturopathy results in an improvement of complaints, impairments, quality of life…
- Trial name
- InteChron (NCT04927403)
- Testing
- multimodal integrative naturopathic therapy concept
- Where
- 3 sites in Germany
- Volunteers
- 1,000 people
- Sponsor
- Universität Duisburg-Essen
Muscle Weakness, Sepsis
Evaluating Muscle Weakness Improvement With Lorcaserin in ICU
ICU acquired muscle weakness is a significant problem in patients recovering from critical illness. This trial will evaluate the safety and efficacy of a drug in improving muscle weakness in critically ill patients.
- Trial name
- EMILI (NCT02523690)
- Testing
- Lorcaserin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Johns Hopkins University
Dermatomyositis
Baricitinib in Patients With Relapsing or naïve Dermatomyositis
Dermatomyositis (DM) is a rare and disabling condition with an important impairment of quality of life and possible life-threatening complications.
- Trial name
- BIRD (NCT04972760)
- Testing
- Baricitinib
- Where
- France
- Volunteers
- 62 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Myositis, Juvenile
Exercise, Creatine and Coenzyme Q10 for Childhood Myositis
Children with Juvenile Idiopathic Inflammatory Myopathies (JIIM) are weak and get tired because their muscles aren't able to work like healthy muscles.
- Trial name
- NCT04286178
- Testing
- creatine monohydrate, ubiquinol, glucose tablet
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- The Hospital for Sick Children
Juvenile Idiopathic Arthritis, Juvenile Rheumatoid Arthritis
Transition to Adulthood Through Coaching and Empowerment in Rheumatology
TRACER is a study aiming to investigate the feasibility of transition coaching sessions for patients moving from paediatric to adult rheumatology care.
- Conditions
- Juvenile Idiopathic Arthritis, Juvenile Rheumatoid Arthritis, Juvenile Dermatomyositis, Juvenile Psoriatic Arthritis
- Trial name
- TRACER (NCT05545839)
- Testing
- Transition coaching
- Where
- 2 sites in Canada
- Volunteers
- 26 people
- Sponsor
- McMaster University
Myositis, Inclusion Body Myositis
Study of Pioglitazone in Sporadic Inclusion Body Myositis
A study looking at the effect of pioglitazone in skeletal muscle of patients with sporadic inclusion body myositis (sIBM).
- Conditions
- Myositis, Inclusion Body Myositis, Muscular Diseases, Musculoskeletal Disease
- Trial name
- NCT03440034
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Johns Hopkins University
Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies
Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases
Main purpose: To evaluate the safety of UTAA09 injection in the treatment of relapsed/refractory (R/R) autoimmune disease (AID).
- Conditions
- Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Systemic Sclerosis, IgG4 Related Disease
- Trial name
- NCT06361745
- Testing
- T cell injection targeting CD19 chimeric antigen receptor
- Where
- China
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Critical Illness, Acute Kidney Injury
Collective Accuryn Physiologic Signals and Signatures
The CAPSS Study is a retrospective and prospective, multi-center, single-arm post-market data collection study with an FDA cleared device.
- Conditions
- Critical Illness, Acute Kidney Injury, Sepsis, Septic Shock
- Trial name
- CAPSS (NCT03817281)
- Testing
- Accuryn Monitoring System
- Where
- United States
- Sponsor
- Potrero Medical
Septic Shock
Interest of Plasma microRNAs
ICU acquired muscle weakness (IAMW) is a common disease that is associated with high morbidity and mortality. Patients with septic shock are particularly at risk.
- Trial name
- µARN (NCT02464371)
- Testing
- kinetic of microRNAs
- Where
- 2 sites in France
- Volunteers
- 58 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Systemic Lupus Erythematosus (SLE), ANCA Associated Vasculitis (AAV)
IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy
This is an exploratory trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of a single dose of IMPT-514, an autologous, anti-CD19/CD20 CAR T therapy, administered as an intravenous (IV)…
- Conditions
- Systemic Lupus Erythematosus (SLE), ANCA Associated Vasculitis (AAV), Idiopathic Inflammatory Myopathy (IIM)
- Trial name
- NCT06462144
- Testing
- IMPT-514 CART Cell Injection
- Where
- 3 sites in China
- Volunteers
- 3 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School